Thu, Apr 3, 4:20 PM, Zacks Good News for Keryx - Analyst Blog Keryx Biopharmaceuticals received good news when the European Medicines Agency (EMA) determined its Marketing Authorization Application (MAA) for lead candidate Zerenex as valid.
Thu, Mar 13, 11:19 AM, Zacks Wider Q4 Loss at Keryx - Analyst Blog Keryx Biopharmaceuticals reported a loss of 21 cents in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 19 cents per share.
Keryx Biopharmaceuticals is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease. Co. is developing Zerenex™ (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Co. has completed a clinical program for Zerenex for the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis. Co. is also developing Zerenex for the management of phosphorus and iron deficiency in anemic patients with non-dialysis dependent chronic kidney disease.
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.